Nabla Bio

Nabla Bio is a biotechnology company founded in 2020 that focuses on developing selective and functional drugs for previously undruggable targets, such as GPCRs, ion channels, and transporters.

The company utilizes artificial intelligence and wet-lab technologies, with its core offering being the AbMapTM Platform, also known as the JAM platform. This platform employs a multimodal generative modeling system to engineer antibodies and protein therapeutics with high precision. Nabla Bio operates on a B2B model, providing access to its platform through licensing agreements, partnerships, and collaborative projects. The company collaborates with leading pharmaceutical companies and biotech firms, including AstraZeneca, Bristol Myers Squibb, and Takeda, to enhance drug pipelines. Nabla Bio has secured significant funding, totaling $37 million, and is headquartered in Cambridge, Massachusetts. The team consists of experts in AI and protein design, and the company continues to grow by recruiting talent in machine learning and synthetic biology.